dc.contributor.author |
Liew, Lydia P |
|
dc.contributor.author |
Shome, Avik |
|
dc.contributor.author |
Wong, Way W |
|
dc.contributor.author |
Hong, Cho R |
|
dc.contributor.author |
Hicks, Kevin O |
|
dc.contributor.author |
Jamieson, Stephen MF |
|
dc.contributor.author |
Hay, Michael P |
|
dc.coverage.spatial |
Switzerland |
|
dc.date.accessioned |
2024-03-14T01:00:02Z |
|
dc.date.available |
2024-03-14T01:00:02Z |
|
dc.date.issued |
2023-05 |
|
dc.identifier.citation |
(2023). Molecules, 28(11), 4457-. |
|
dc.identifier.issn |
1420-3049 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/67728 |
|
dc.description.abstract |
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiotherapy herald new opportunities for classical oxygen-mimetic radiosensitisers. Only nimorazole is used clinically as a radiosensitiser, and there is a dearth of new radiosensitisers in development. In this report, we augment previous work to present new nitroimidazole alkylsulfonamides and we document their cytotoxicity and ability to radiosensitise anoxic tumour cells in vitro. We compare radiosensitisation with etanidazole and earlier nitroimidazole sulfonamide analogues and we identify 2-nitroimidazole and 5-nitroimidazole analogues with marked tumour radiosensitisation in ex vivo assays of surviving clonogens and with in vivo tumour growth inhibition. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
MDPI |
|
dc.relation.ispartofseries |
Molecules (Basel, Switzerland) |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Humans |
|
dc.subject |
Neoplasms |
|
dc.subject |
Nitroimidazoles |
|
dc.subject |
Radiation-Sensitizing Agents |
|
dc.subject |
Cell Hypoxia |
|
dc.subject |
Hypoxia |
|
dc.subject |
DNA damage |
|
dc.subject |
chemoradiotherapy |
|
dc.subject |
electron affinity |
|
dc.subject |
nitroimidazole |
|
dc.subject |
prodrugs |
|
dc.subject |
radiosensitisers |
|
dc.subject |
radiotherapy |
|
dc.subject |
sulfonamide |
|
dc.subject |
tumour microenvironment |
|
dc.subject |
3404 Medicinal and Biomolecular Chemistry |
|
dc.subject |
3405 Organic Chemistry |
|
dc.subject |
34 Chemical Sciences |
|
dc.subject |
5 Development of treatments and therapeutic interventions |
|
dc.subject |
5.5 Radiotherapy and other non-invasive therapies |
|
dc.subject |
Cancer |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Physical Sciences |
|
dc.subject |
Biochemistry & Molecular Biology |
|
dc.subject |
Chemistry, Multidisciplinary |
|
dc.subject |
Chemistry |
|
dc.subject |
HYPOXIC CELL RADIOSENSITIZERS |
|
dc.subject |
STEREOTACTIC ABLATIVE RADIOTHERAPY |
|
dc.subject |
BODY RADIATION-THERAPY |
|
dc.subject |
PHASE-III TRIAL |
|
dc.subject |
NUCLEOSIDE ANALOG |
|
dc.subject |
NECK-CANCER |
|
dc.subject |
TUMOR HYPOXIA |
|
dc.subject |
EARLY-STAGE |
|
dc.subject |
HEAD |
|
dc.subject |
CARCINOMA |
|
dc.subject |
0304 Medicinal and Biomolecular Chemistry |
|
dc.subject |
0305 Organic Chemistry |
|
dc.subject |
0307 Theoretical and Computational Chemistry |
|
dc.title |
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.3390/molecules28114457 |
|
pubs.issue |
11 |
|
pubs.begin-page |
4457 |
|
pubs.volume |
28 |
|
dc.date.updated |
2024-02-08T21:00:39Z |
|
dc.rights.holder |
Copyright: The authors |
en |
dc.identifier.pmid |
37298933 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/37298933 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
research-article |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
964921 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
Science |
|
pubs.org-id |
Science Research |
|
pubs.org-id |
Medical Sciences |
|
pubs.org-id |
Auckland Cancer Research |
|
pubs.org-id |
Pharmacology |
|
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
|
dc.identifier.eissn |
1420-3049 |
|
dc.identifier.pii |
molecules28114457 |
|
pubs.number |
ARTN 4457 |
|
pubs.record-created-at-source-date |
2024-02-09 |
|
pubs.online-publication-date |
2023-05-31 |
|